# Gyre Therapeutics, Inc.: overview GYRE · Nasdaq · CIK 1124105 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/gyre.md) · [Financials](/companies/gyre/financials.md) · [Filings](/companies/gyre/filings.md) · [Insiders](/companies/gyre/insiders.md) Latest reported revenue: [$29.1m](/filings/0001193125-26-340448.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 7, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-340448). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [25.5](/filings/0001193125-25-272383.md) | [27.9 d](/filings/0001193125-26-106251.md) | [22.1](/filings/0001193125-26-214676.md) | [29.7](/filings/0001193125-26-340448.md) | [30.6](/filings/0001193125-25-272383.md) | [37.2 d](/filings/0001193125-26-106251.md) | [22.5](/filings/0001193125-26-214676.md) | [29.1](/filings/0001193125-26-340448.md) | | Gross margin | % | [96.2%](/filings/0001193125-25-272383.md) | [95.8% d](/filings/0000950170-25-040279.md) | [95.9%](/filings/0000950170-25-068089.md) | [86.2%](/filings/0000950170-25-106644.md) | [94.7%](/filings/0001193125-25-272383.md) | not reported | not reported | not reported | | Operating margin | % | [16.6%](/filings/0001193125-25-272383.md) | [2.4% d](/filings/0001193125-26-106251.md) | [10.3%](/filings/0001193125-26-214676.md) | [(7.5%)](/filings/0001193125-26-340448.md) | [22.7%](/filings/0001193125-25-272383.md) | [0.3% d](/filings/0001193125-26-106251.md) | [(41.5%)](/filings/0001193125-26-214676.md) | [(49.3%)](/filings/0001193125-26-340448.md) | | Net margin | % | [11.2%](/filings/0001193125-25-272383.md) | [2.1% d](/filings/0001193125-26-106251.md) | [22.4%](/filings/0001193125-26-340448.md) | [(7.5%)](/filings/0001193125-26-340448.md) | [19.4%](/filings/0001193125-25-272383.md) | [(3.5%) d](/filings/0001193125-26-106251.md) | [(82.5%)](/filings/0001193125-26-340448.md) | [(49.0%)](/filings/0001193125-26-340448.md) | | Diluted EPS | $ per share | [0.01](/filings/0001193125-25-272383.md) | not reported | [0.00](/filings/0001193125-26-214676.md) | [(0.03)](/filings/0001193125-26-340448.md) | [0.03](/filings/0001193125-25-272383.md) | not reported | [(0.10)](/filings/0001193125-26-214676.md) | [(0.12)](/filings/0001193125-26-340448.md) | | Free cash flow | $m | [1.0 d](/filings/0001193125-25-272383.md) | [(2.8) d](/filings/0001193125-26-106251.md) | [(0.3)](/filings/0001193125-26-214676.md) | [(7.8) d](/filings/0001193125-26-340448.md) | [13.6 d](/filings/0001193125-25-272383.md) | [(5.8) d](/filings/0001193125-26-106251.md) | [3.0](/filings/0001193125-26-214676.md) | [(17.0) d](/filings/0001193125-26-340448.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [7.3](/filings/0001564590-22-012877.md) | [102](/filings/0000950170-24-037242.md) | [113](/filings/0000950170-25-040279.md) | [106](/filings/0001193125-26-106251.md) | [117](/filings/0001193125-26-106251.md) | | Gross margin | % | not reported | [95.3%](/filings/0000950170-24-037242.md) | [95.9%](/filings/0000950170-25-040279.md) | [96.3%](/filings/0000950170-25-040279.md) | not reported | | Operating margin | % | [(1197.8%)](/filings/0001564590-23-004830.md) | [9.0%](/filings/0000950170-24-037242.md) | [(59.3%)](/filings/0000950170-25-040279.md) | [15.3%](/filings/0001193125-26-106251.md) | [9.9%](/filings/0001193125-26-106251.md) | | Net margin | % | [(1198.3%)](/filings/0001564590-23-004830.md) | [4.2%](/filings/0000950170-24-037242.md) | [(75.3%)](/filings/0000950170-25-040279.md) | [16.9%](/filings/0001193125-26-106251.md) | [8.5%](/filings/0001193125-26-106251.md) | | Diluted EPS | $ per share | [(2.87)](/filings/0001564590-23-004830.md) | [0.03](/filings/0000950170-24-037242.md) | [(1.41)](/filings/0000950170-25-040279.md) | [0.05](/filings/0001193125-26-106251.md) | [0.02](/filings/0001193125-26-106251.md) | | Free cash flow | $m | [(84.6)](/filings/0001564590-23-004830.md) | [5.7](/filings/0000950170-24-037242.md) | [17.4](/filings/0000950170-25-040279.md) | [(6.0)](/filings/0001193125-26-106251.md) | [(0.2)](/filings/0001193125-26-106251.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax; Gross profit: us-gaap:GrossProfit. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gyre/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [HSG Holding Ltd](/funds/1470766.md) | 2026-06-30 | $24.7m | 3,750,299 | | New +3,750,299 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $6.6m | 993,943 | | Added +235,313 | | [Octagon Capital Advisors LP](/funds/1839435.md) | 2026-06-30 | $6.3m | 954,416 | | New +954,416 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.8m | 876,927 | | Reduced −107,277 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $3.5m | 532,950 | | Added +101,536 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $1.6m | 245,402 | | Added +29,076 | | [CHARLES SCHWAB INVESTMENT MANAGEMENT INC](/funds/884546.md) | 2026-06-30 | $1.2m | 184,286 | | Added +19,048 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $1.1m | 169,537 | | Added +35,696 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $1.1m | 166,750 | | Reduced −4,087 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $995.6k | 151,073 | | Added +13,391 | ## Recent filings [All 1,376 filings](/companies/gyre/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-22 | 20:01 ET | [8-K](/filings/0001140361-26-040506.md) | 5.02 Departure or appointment of officers or directors; 9.01 Financial statements and exhibits | 0001140361-26-040506 | | 2026-09-01 | 13:00 ET | [8-K](/filings/0001140361-26-035189.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-035189 | | 2026-08-26 | 13:00 ET | [8-K](/filings/0001140361-26-034401.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-034401 | | 2026-08-07 | 21:00 ET | [10-Q](/filings/0001193125-26-340448.md) | Quarterly report, period 2026-06-30 | 0001193125-26-340448 | | 2026-08-07 | 12:00 ET | [8-K](/filings/0001193125-26-339223.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001193125-26-339223 | | 2026-07-16 | 20:35 ET | [8-K](/filings/0001140361-26-028716.md) | 5.02 Departure or appointment of officers or directors; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-028716 | | 2026-07-15 | 21:09 ET | [8-K/A](/filings/0001140361-26-028564.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001140361-26-028564 | | 2026-06-16 | 10:30 ET | [8-K](/filings/0001140361-26-025324.md) | 5.07 Shareholder vote results | 0001140361-26-025324 | | 2026-06-02 | 10:09 ET | [8-K](/filings/0001140361-26-023625.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-023625 | | 2026-05-14 | 21:25 ET | [8-K](/filings/0001140361-26-021360.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001140361-26-021360 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-106251.md), filed Mar 13, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/c0ba9c83-0ec3-4e9f-b0b6-a1099efd7873) ## About the filer - CIK: 1124105 - Tickers: GYRE - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:34 ET. No prices; not investment advice.